168 related articles for article (PubMed ID: 25843419)
1. Dasatinib enhances cisplatin sensitivity in human esophageal squamous cell carcinoma (ESCC) cells via suppression of PI3K/AKT and Stat3 pathways.
Chen J; Lan T; Zhang W; Dong L; Kang N; Fu M; Liu B; Liu K; Zhang C; Hou J; Zhan Q
Arch Biochem Biophys; 2015 Jun; 575():38-45. PubMed ID: 25843419
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of cell growth and up-regulation of MAD2 in human oesophageal squamous cell carcinoma after treatment with the Src/Abl inhibitor dasatinib.
Wang L; Guo B; Wang R; Jiang Y; Qin S; Liang S; Zhao Y; Guo W; Li K; Fan X
Clin Sci (Lond); 2012 Jan; 122(1):13-24. PubMed ID: 21751967
[TBL] [Abstract][Full Text] [Related]
3. ALC1 knockdown enhances cisplatin cytotoxicity of esophageal squamous cell carcinoma cells by inhibition of glycolysis through PI3K/Akt pathway.
Li F; Zhang Z; Wang P; Wen P; Xu Q; Wang Y; Pan P; Ma L
Life Sci; 2019 Sep; 232():116679. PubMed ID: 31340168
[TBL] [Abstract][Full Text] [Related]
4. Shp2 Inhibits Proliferation of Esophageal Squamous Cell Cancer via Dephosphorylation of Stat3.
Qi C; Han T; Tang H; Huang K; Min J; Li J; Ding X; Xu Z
Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28085101
[TBL] [Abstract][Full Text] [Related]
5. Phosphatidylinositol 3-kinase-C2β inhibits cisplatin-mediated apoptosis via the Akt pathway in oesophageal squamous cell carcinoma.
Liu Z; Sun C; Zhang Y; Ji Z; Yang G
J Int Med Res; 2011; 39(4):1319-32. PubMed ID: 21986133
[TBL] [Abstract][Full Text] [Related]
6. MicroRNA-125a-5p enhances the sensitivity of esophageal squamous cell carcinoma cells to cisplatin by suppressing the activation of the STAT3 signaling pathway.
Zhao Y; Ma K; Yang S; Zhang X; Wang F; Zhang X; Liu H; Fan Q
Int J Oncol; 2018 Aug; 53(2):644-658. PubMed ID: 29767234
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-126 is down-regulated in human esophageal squamous cell carcinoma and inhibits the proliferation and migration in EC109 cell via PI3K/AKT signaling pathway.
Nie ZC; Weng WH; Shang YS; Long Y; Li J; Xu YT; Li Z
Int J Clin Exp Pathol; 2015; 8(5):4745-54. PubMed ID: 26191164
[TBL] [Abstract][Full Text] [Related]
8. Catalytically defective receptor protein tyrosine kinase PTK7 enhances invasive phenotype by inducing MMP-9 through activation of AP-1 and NF-κB in esophageal squamous cell carcinoma cells.
Shin WS; Hong Y; Lee HW; Lee ST
Oncotarget; 2016 Nov; 7(45):73242-73256. PubMed ID: 27689325
[TBL] [Abstract][Full Text] [Related]
9. Calreticulin promotes cell motility and enhances resistance to anoikis through STAT3-CTTN-Akt pathway in esophageal squamous cell carcinoma.
Du XL; Yang H; Liu SG; Luo ML; Hao JJ; Zhang Y; Lin DC; Xu X; Cai Y; Zhan QM; Wang MR
Oncogene; 2009 Oct; 28(42):3714-22. PubMed ID: 19684620
[TBL] [Abstract][Full Text] [Related]
10. miR-18a promotes cell proliferation of esophageal squamous cell carcinoma cells by increasing cylin D1 via regulating PTEN-PI3K-AKT-mTOR signaling axis.
Zhang W; Lei C; Fan J; Wang J
Biochem Biophys Res Commun; 2016 Aug; 477(1):144-149. PubMed ID: 27291152
[TBL] [Abstract][Full Text] [Related]
11. STAT3 expression, activity and functional consequences of STAT3 inhibition in esophageal squamous cell carcinomas and Barrett's adenocarcinomas.
Timme S; Ihde S; Fichter CD; Waehle V; Bogatyreva L; Atanasov K; Kohler I; Schöpflin A; Geddert H; Faller G; Klimstra D; Tang L; Reinheckel T; Hauschke D; Busch H; Boerries M; Werner M; Lassmann S
Oncogene; 2014 Jun; 33(25):3256-66. PubMed ID: 23912451
[TBL] [Abstract][Full Text] [Related]
12. XPD inhibits cell growth and invasion and enhances chemosensitivity in esophageal squamous cell carcinoma by regulating the PI3K/AKT signaling pathway.
Jian J; Li S; Liu LZ; Zhen L; Yao L; Gan LH; Huang YQ; Fang N
Int J Mol Med; 2020 Jul; 46(1):201-210. PubMed ID: 32377720
[TBL] [Abstract][Full Text] [Related]
13. Krüppel-Like Factor 4 Enhances Sensitivity of Cisplatin to Esophageal Squamous Cell Carcinoma (ESCC) Cells.
Chen C; Ma Z; Zhang H; Liu X; Yu Z
Med Sci Monit; 2017 Jul; 23():3353-3359. PubMed ID: 28694421
[TBL] [Abstract][Full Text] [Related]
14. TRAP1 shows clinical significance and promotes cellular migration and invasion through STAT3/MMP2 pathway in human esophageal squamous cell cancer.
Ou Y; Liu L; Xue L; Zhou W; Zhao Z; Xu B; Song Y; Zhan Q
J Genet Genomics; 2014 Oct; 41(10):529-37. PubMed ID: 25438697
[TBL] [Abstract][Full Text] [Related]
15. siRNA-mediated downregulation of TC21 sensitizes esophageal cancer cells to cisplatin.
Hasan R; Chauhan SS; Sharma R; Ralhan R
World J Gastroenterol; 2012 Aug; 18(31):4127-35. PubMed ID: 22919244
[TBL] [Abstract][Full Text] [Related]
16. Increased expression of EIF5A2, via hypoxia or gene amplification, contributes to metastasis and angiogenesis of esophageal squamous cell carcinoma.
Li Y; Fu L; Li JB; Qin Y; Zeng TT; Zhou J; Zeng ZL; Chen J; Cao TT; Ban X; Qian C; Cai Z; Xie D; Huang P; Guan XY
Gastroenterology; 2014 Jun; 146(7):1701-13.e9. PubMed ID: 24561231
[TBL] [Abstract][Full Text] [Related]
17. Focal adhesion kinase (FAK) inhibitor-defactinib suppresses the malignant progression of human esophageal squamous cell carcinoma (ESCC) cells via effective blockade of PI3K/AKT axis and downstream molecular network.
Zhang L; Zhao D; Wang Y; Zhang W; Zhang J; Fan J; Zhan Q; Chen J
Mol Carcinog; 2021 Feb; 60(2):113-124. PubMed ID: 33283357
[TBL] [Abstract][Full Text] [Related]
18. RUNX3 reverses cisplatin resistance in esophageal squamous cell carcinoma via suppression of the protein kinase B pathway.
Li DJ; Shi M; Wang Z
Thorac Cancer; 2016 Sep; 7(5):570-580. PubMed ID: 27766776
[TBL] [Abstract][Full Text] [Related]
19. Abrogation of signal transducer and activator of transcription 3 reactivation after Src kinase inhibition results in synergistic antitumor effects.
Johnson FM; Saigal B; Tran H; Donato NJ
Clin Cancer Res; 2007 Jul; 13(14):4233-44. PubMed ID: 17634553
[TBL] [Abstract][Full Text] [Related]
20. ZD1839 (Gefitinib, 'Iressa'), an epidermal growth factor receptor-tyrosine kinase inhibitor, enhances the anti-cancer effects of TRAIL in human esophageal squamous cell carcinoma.
Teraishi F; Kagawa S; Watanabe T; Tango Y; Kawashima T; Umeoka T; Nisizaki M; Tanaka N; Fujiwara T
FEBS Lett; 2005 Aug; 579(19):4069-75. PubMed ID: 16023108
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
